Expanding business opportunities in Japan and accelerating 바카라사이트 벳페어 operations
[by Yu, Suin] 바카라사이트 벳페어, an AI-based company specializing in the diagnosis and treatment of brain diseases, announced on August 26 the appointment of Dr. Atsushi Iwata, M.D., Ph.D., vice president of the Tokyo Metropolitan Institute for Geriatrics and Gerontology and professor at the University of Tokyo Hospital, as a member of its Scientific Advisory Board (SAB).
The company stated that Dr. Iwata’s appointment to the SAB is intended to provide comprehensive medical and business guidance on the technical validation of Neurophet's products, the formulation of research and development (R&D) strategies, and the course of global commercialization, including expansion into the Japanese market.
Dr. Iwata, a neurologist and a world-renowned authority in behavioral neuroscience and neuroimaging, currently serves as Director of the Outpatient Clinic at the University of Tokyo Hospital. He engages in advisory work and collaborative research with the Japanese pharmaceutical company Eisai and is one of the leading prescribers in Japan of LEQEMBI (lecanemab), an anti-amyloid treatment. In addition, he plays a pivotal role in clinical trials conducted under the Japanese Alzheimer’s Disease Neuroimaging Initiative (Japanese ADNI).
Iwata will contribute technical and medical guidance on Neurophet's R&D efforts in Alzheimer's disease brain imaging analysis while also advising on the company’s business direction in Japan. In addition, he will support the expansion of Neurophet's global network by engaging in discussions on partnership opportunities with international Key Opinion Leaders (KOLs) and industry partners.
"The collaboration with Dr. Iwata will not only secure global trust in our technological capabilities but also serve as a key turning point for our entry into the Japanese market. We aim to reinforce our global competitiveness by creating strong synergy between our R&D and commercialization strategies," said Jake Junkil Been, Co-CEO of Neurophet.
On the other hand, 바카라사이트 벳페어 is accelerating its overseas expansion alongside collaborations with major global pharmaceutical companies. In Japan, 바카라사이트 벳페어 AQUA, 바카라사이트 벳페어 SCALE PET, and 바카라사이트 벳페어 AQUA AD have been officially certified by the Japan Radiological Society (JRS) as products eligible for additional reimbursement under Japan's National Health Insurance system. Building on this recognition, 바카라사이트 벳페어 has partnered with Hokuyaku Takeyama Holdings, a Japanese medical device and pharmaceutical distributor with annual sales of KRW 2 trillion (approximately USD 1.4 billion), and is moving swiftly to expand its presence among medical institutions across Japan.